Literature DB >> 16622201

Expression of Haemophilus ducreyi collagen binding outer membrane protein NcaA is required for virulence in swine and human challenge models of chancroid.

Robert A Fulcher1, Leah E Cole, Diane M Janowicz, Kristen L Toffer, Kate R Fortney, Barry P Katz, Paul E Orndorff, Stanley M Spinola, Thomas H Kawula.   

Abstract

Haemophilus ducreyi, the etiologic agent of the sexually transmitted genital ulcer disease chancroid, has been shown to associate with dermal collagen fibers within infected skin lesions. Here we describe NcaA, a previously uncharacterized outer membrane protein that is important for H. ducreyi collagen binding and host colonization. An H. ducreyi strain lacking the ncaA gene was impaired in adherence to type I collagen but not fibronectin (plasma or cellular form) or heparin. The mutation had no effect on serum resistance or binding to HaCaT keratinocytes or human foreskin fibroblasts in vitro. Escherichia coli expressing H. ducreyi NcaA bound to type I collagen, demonstrating that NcaA is sufficient to confer collagen attachment. The importance of NcaA in H. ducreyi pathogenesis was assessed using both swine and human experimental models of chancroid. In the swine model, 20% of lesions from sites inoculated with the ncaA mutant were culture positive for H. ducreyi 7 days after inoculation, compared to 73% of wild-type-inoculated sites. The average number of CFU recovered from mutant-inoculated lesions was also significantly reduced compared to that recovered from wild-type-inoculated sites at both 2 and 7 days after inoculation. In the human challenge model, 8 of 30 sites inoculated with wild-type H. ducreyi progressed to the pustular stage, compared to 0 of 30 sites inoculated with the ncaA mutant. Together these results demonstrate that the collagen binding protein NcaA is required for H. ducreyi infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622201      PMCID: PMC1459755          DOI: 10.1128/IAI.74.5.2651-2658.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

1.  Genetic analysis of virulence plasmid from a serogroup 9 Yersinia enterocolitica strain: role of outer membrane protein P1 in resistance to human serum and autoagglutination.

Authors:  G Balligand; Y Laroche; G Cornelis
Journal:  Infect Immun       Date:  1985-06       Impact factor: 3.441

2.  Serum resistance in Haemophilus ducreyi requires outer membrane protein DsrA.

Authors:  C Elkins; K J Morrow; B Olsen
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  The collagen-binding adhesin is a virulence factor in Staphylococcus aureus keratitis.

Authors:  M N Rhem; E M Lech; J M Patti; D McDevitt; M Höök; D B Jones; K R Wilhelmus
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  An isogenic hemoglobin receptor-deficient mutant of Haemophilus ducreyi is attenuated in the human model of experimental infection.

Authors:  J A Al-Tawfiq; K R Fortney; B P Katz; A F Hood; C Elkins; S M Spinola
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Four different genes responsible for nonimmune immunoglobulin-binding activities within a single strain of Escherichia coli.

Authors:  C H Sandt; C W Hill
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection.

Authors:  K R Fortney; R S Young; M E Bauer; B P Katz; A F Hood; R S Munson; S M Spinola
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

7.  Evaluation of an isogenic major outer membrane protein-deficient mutant in the human model of Haemophilus ducreyi infection.

Authors:  R E Throm; J A Al-Tawfiq; K R Fortney; B P Katz; A F Hood; C A Slaughter; E J Hansen; S M Spinola
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Thermoregulation-dependent expression of Yersinia enterocolitica protein 1 imparts serum resistance to Escherichia coli K-12.

Authors:  R J Martinez
Journal:  J Bacteriol       Date:  1989-07       Impact factor: 3.490

9.  The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis.

Authors:  J M Patti; T Bremell; D Krajewska-Pietrasik; A Abdelnour; A Tarkowski; C Rydén; M Höök
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Genital ulceration as a risk factor for human immunodeficiency virus infection.

Authors:  R M Greenblatt; S A Lukehart; F A Plummer; T C Quinn; C W Critchlow; R L Ashley; L J D'Costa; J O Ndinya-Achola; L Corey; A R Ronald
Journal:  AIDS       Date:  1988-02       Impact factor: 4.177

View more
  17 in total

1.  Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humans.

Authors:  Stanley M Spinola; Wei Li; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Barry P Katz; Robert S Munson
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication.

Authors:  Diane M Janowicz; Klara Tenner-Racz; Paul Racz; Tricia L Humphreys; Carol Schnizlein-Bick; Kate R Fortney; Beth Zwickl; Barry P Katz; James J Campbell; David D Ho; Stanley M Spinola
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

3.  Outer membrane protein DsrA is the major fibronectin-binding determinant of Haemophilus ducreyi.

Authors:  Isabelle Leduc; C Dinitra White; Igor Nepluev; Robert E Throm; Stanley M Spinola; Christopher Elkins
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

4.  Complete genome sequence of Haemophilus somnus (Histophilus somni) strain 129Pt and comparison to Haemophilus ducreyi 35000HP and Haemophilus influenzae Rd.

Authors:  Jean F Challacombe; A J Duncan; Thomas S Brettin; David Bruce; Olga Chertkov; J Chris Detter; Cliff S Han; Monica Misra; Paul Richardson; Roxanne Tapia; Nina Thayer; Gary Xie; Thomas J Inzana
Journal:  J Bacteriol       Date:  2006-12-15       Impact factor: 3.490

5.  A Class I Haemophilus ducreyi Strain Containing a Class II hgbA Allele Is Partially Attenuated in Humans: Implications for HgbA Vaccine Efficacy Trials.

Authors:  Isabelle Leduc; Kate R Fortney; Diane M Janowicz; Beth Zwickl; Sheila Ellinger; Barry P Katz; Huaiying Lin; Qunfeng Dong; Stanley M Spinola
Journal:  Infect Immun       Date:  2019-06-20       Impact factor: 3.441

6.  Haemophilus ducreyi Outer membrane determinants, including DsrA, define two clonal populations.

Authors:  Catherine Dinitra White; Isabelle Leduc; Bonnie Olsen; Chrystina Jeter; Chavala Harris; Christopher Elkins
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

7.  Trimeric autotransporter DsrA is a major mediator of fibrinogen binding in Haemophilus ducreyi.

Authors:  William G Fusco; Christopher Elkins; Isabelle Leduc
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

8.  Haemophilus ducreyi LspA proteins are tyrosine phosphorylated by macrophage-encoded protein tyrosine kinases.

Authors:  Kaiping Deng; Jason R Mock; Steven Greenberg; Nicolai S C van Oers; Eric J Hansen
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

9.  Dysregulated immune profiles for skin and dendritic cells are associated with increased host susceptibility to Haemophilus ducreyi infection in human volunteers.

Authors:  Tricia L Humphreys; Lang Li; Xiaoman Li; Diane M Janowicz; Kate R Fortney; Qianqian Zhao; Wei Li; Jeanette McClintick; Barry P Katz; David S Wilkes; Howard J Edenberg; Stanley M Spinola
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

10.  Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience.

Authors:  Diane M Janowicz; Susan Ofner; Barry P Katz; Stanley M Spinola
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.